Terapia con [177Lu – Dota0 – Tyr3]-Octreotate (177Lu- Dotatate) en pacientes con tumores avanzados de origen neuroendocrino: experiencia inicial y resultados preliminares

Translated title of the contribution: Therapy with [177Lu - Dota0 - Tyr3]-Octreotate (177Lu-Dotatate) in patients with advanced neuroendocrine tumors: Initial experience and preliminary results

Víctor Marín-Oyaga, Claudia Gutiérrez-Villamil, Arturo Mejía-López, Alex Valenzuela-Rincón, Gabriel Sánchez de Guzmán, José Sinay Arévalo-Leal

Research output: Contribution to journalArticlepeer-review


Objective: To Show the initial experience and preliminary results of therapy with [177Lu-Dota0- Tyr3] - Octreotate (177 Lu-Dotatate) in patients with neuroendocrine tumors (net) treated in our institution, because the experience gained from this practice in Latin American countries is poorly known. Materials and methods: A descriptive and retrospective analysis in patients who have undergone therapy with 177 Lu-Dotatate with at least one dose and at least one year of follow-up was performed. 8 patients (4 women and 4 men) with a mean age of 57 years (50-63) were included. A total of 24 doses were given, an average of 3 doses per patient. A total of 187 GBq were administered, equivalent to 23.5 GBq / patient. Response to therapy and the presence of adverse short and long term effects were assessed. Results: The average follow-up time was 46 months (26-72 months). 5/8 patients were diagnosed with pancreatic net, 2/8 of gastric origin and 1/8 of small bowel origin. 7/8 patients had metastatic involvement and 1/8 patient despite not having metastasis was considered unresectable. 6/8 patients had mild post-therapy symptoms and 1/8 serious adverse events. 2/8 patients had partial response, 4/8 stable disease and 2/8 had a complete response. At the end of follow-up, however, one patient who had a complete response presented with recurrence and one with partial response showed progression and death. Conclusions: In our experience, therapy with 177 Lu-Dotatate was safe and effective in patients with net as an alternative therapy with appropriate levels of response and disease control and with mild expected adverse events and self-limiting minimum serious events.

Translated title of the contributionTherapy with [177Lu - Dota0 - Tyr3]-Octreotate (177Lu-Dotatate) in patients with advanced neuroendocrine tumors: Initial experience and preliminary results
Original languageSpanish
Pages (from-to)335-344
Number of pages10
JournalRevista ciencias de la salud
Issue number3
StatePublished - Oct 5 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Health(social science)

Author Keywords

  • Concept

Cite this